Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia.
1. A method of treating hypophosphatemia in a subject, said method comprising:
selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and
administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor ternary complex formation under conditions effective to treat the hypophosphatemia, wherein the inhibitor is a peptide consisting of the amino acid sequence of SEQ ID NO:12 or amino acid residues 1 to 21 of SEQ ID NO:11.
2. The method according to claim 1 , wherein Klotho has the amino acid sequence of SEQ ID NO:7.
3. The method according to claim 1 , wherein the FGF23 has the amino acid sequence of SEQ ID NO:3.
4. The method according to claim 1 , wherein the FGF receptor has the amino acid sequence of SEQ ID NO:9.
5. The method according to claim 1 , wherein said administering is carried out orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, transdermally, or by application to mucous membranes.
6. The method according to claim 1 , wherein the inhibitor is administered with a pharmaceutically-acceptable carrier.
7. The method according to claim 1 , wherein the subject is a mammal.
8. The method according to claim 7 , wherein the subject is a human.
9. The method according to claim 1 , wherein the hypophosphatemia is due to autosomal dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemia (XLH), autosomal recessive hypophosphatemic rickets (ARHR), fibrous dysplasia (FD), McCune-Albright syndrome complicated by fibrous dysplasia (MAS/FD), Jansen's metaphyseal chondrodysplasia (Jansen's Syndrome), tumor-induced osteomalacia (TIO), autosomal dominant polycystic kidney disease (ADPKD), chronic metabolic acidosis, or any other inherited or acquired renal phosphate wasting disorder.
10. The method according to claim 1 , wherein the hypophosphatemia is due to alcoholic and diabetic ketoacidosis, acute asthma, chronic obstructive pulmonary disease, drug treatment of asthma, drug treatment of chronic obstructive pulmonary disease, mechanical ventilation, sepsis, recovery from kidney transplantation, parenteral iron administration, salicylate intoxication, severe trauma, chronic treatment with sucralfate and/or antacids, refeeding syndrome, or an eating disorder.
11. The method according to claim 1 , wherein the hypophosphatemia is due to anorexia nervosa or bulimia nervosa.
12. The method according to claim 1 , wherein the inhibitor is the peptide consisting of the amino acid sequence of SEQ ID NO:12.
13. The method according to claim 1 , wherein the inhibitor is the peptide consisting of the amino acid sequence of amino acid residues 1 to 21 of SEQ ID NO:11.
14. A method of treating hypophosphatemia in a subject, said method comprising:
selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and
administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor ternary complex formation under conditions effective to treat the hypophosphatemia, wherein the inhibitor comprises an FGF23 C-terminal fragment consisting of the amino acid sequence of SEQ ID NO:12 or amino acid residues 1 to 21 of SEQ ID NO:11.
15. The method according to claim 14 , wherein Klotho has the amino acid sequence of SEQ ID NO:7.
16. The method according to claim 14 , wherein the FGF23 has the amino acid sequence of SEQ ID NO:3.
17. The method according to claim 14 , wherein the FGF receptor has the amino acid sequence of SEQ ID NO:9.
18. The method according to claim 14 , wherein said administering is carried out orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, transdermally, or by application to mucous membranes.
19. The method according to claim 14 , wherein the inhibitor is administered with a pharmaceutically-acceptable carrier.
20. The method according to claim 14 , wherein the subject is a mammal.
21. The method according to claim 20 , wherein the subject is a human.
22. The method according to claim 14 , wherein the hypophosphatemia is due to autosomal dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemia (XLH), autosomal recessive hypophosphatemic rickets (ARHR), fibrous dysplasia (FD), McCune-Albright syndrome complicated by fibrous dysplasia (MAS/FD), Jansen's metaphyseal chondrodysplasia (Jansen's Syndrome), tumor-induced osteomalacia (TIO), autosomal dominant polycystic kidney disease (ADPKD), chronic metabolic acidosis, or any other inherited or acquired renal phosphate wasting disorder.
23. The method according to claim 14 , wherein the hypophosphatemia is due to alcoholic and diabetic ketoacidosis, acute asthma, chronic obstructive pulmonary disease, drug treatment of asthma, drug treatment of chronic obstructive pulmonary disease, mechanical ventilation, sepsis, recovery from kidney transplantation, parenteral iron administration, salicylate intoxication, severe trauma, chronic treatment with sucralfate and/or antacids, refeeding syndrome, or an eating disorder.
24. The method according to claim 14 , wherein the hypophosphatemia is due to anorexia nervosa or bulimia nervosa.
25. The method according to claim 14 , wherein the FGF23 C-terminal fragment consists of the amino acid sequence of SEQ ID NO:12.
26. The method according to claim 14 , wherein the FGF23 C-terminal fragment consists of the amino acid sequence of amino acid residues 1 to 21 of SEQ ID NO:11.